FDA Rule Would Remove Website Shortcut for Risk Details in TV Drug Ads
核心洞察
HHS and the FDA have listed a proposed rule, "Transparency in Direct-to-Consumer Advertising," on the federal regulatory agenda for December 2026.
The rule would remove the adequate provision option that lets broadcast drug ads point viewers to a website, phone number or magazine for full risk information.
The FDA expects the rule to be economically significant, with annual costs above $100 million for at least one year, and says it is not a ban on advertising.
HHS and the FDA intend to issue a proposed rule in December 2026 that would end the option for television and radio prescription drug ads to satisfy the summary requirement by directing viewers elsewhere for a medication's full risk information. The agenda entry, titled "Transparency in Direct-to-Consumer Advertising," cites a Sept. 9, 2025, presidential memorandum directing the agencies to increase risk information in drug advertising. Nothing is in effect: the entry is a summary rather than draft text, and a public comment period and a separate final rule would follow publication.
Current regulation at 21 C.F.R. 202.1(e) requires broadcast ads to carry a spoken "major statement" of the most important risks and a summary of risk information, unless the ad makes "adequate provision" for viewers to obtain the full FDA-approved prescribing information from another source, such as a health care provider, toll-free number, a current magazine carrying a print ad, or a website. The FDA says the change would require broadcast ads to disclose all relevant risk and safety information within the ad itself. The agency expects annual costs exceeding $100 million for at least one year, and says companies may need to buy more airtime, devote more existing airtime to safety information, or stop advertising. The Mintz FDA regulatory newsletter notes the rulemaking could delete the adequate provision language entirely or substantially modify it.
The FDA says the rule would not ban drug advertising, while attorneys writing on the FDA Law Blog said the added cost could effectively end broadcast drug ads. The agenda entry does not state whether the requirement would extend to social media or streaming ads, a question left open. Approvals, labels, availability and prices are unaffected, and patients would still receive the same prescribing information from their pharmacy. A 2023 FDA final rule already requires the major statement in TV and radio ads to be presented in a clear, conspicuous and neutral manner.